Categories // Breast Cancer Management
Welcome to our round up of the top Oncology Management articles that were published in 2019. Here, we discuss some articles that have been particular highlights of the last year from across the journal series and look at some hot topics from the area of oncology management.
The most read article from across the whole journal series comes from CNS Oncology. Ugonma N Chukwueke and Patrick Y Wen, both from the Dana-Farber Cancer Institute (MA, USA), review the recommendations of the Response Assessment in Neuro-Oncology (RANO) working groups and look at how they may be applied in the routine care of patients with different types of brain tumors. Different RANO groups have been set up for distinct tumor and treatment types, each group aiming to determine relevant and reliable criteria for assessing a patient’s response to their disease and treatment. The criteria developed by the groups has been applied in various clinical trial settings and may be used to aid therapeutic decision making among clinicians. The authors propose that, as understanding of the molecular underpinnings of primary and metastatic brain tumors advance, so will these guidelines. It is a dynamic process and, as a greater amount of data accumulates, the RANO-proposed guidelines will change to reflect this new information. For anyone interested in guidelines for trials or patient care in central nervous system oncology management, this is a key read.
Another highlight this year came from Breast Cancer Management, with a short communication from Tara Sanft (Yale University School of Medicine, CT, USA) et al. that focused on the gene expression-based assay, Breast Cancer Index (BCI). This study investigated the impact of incorporating BCI into the clinic and the effect this will have on extended endocrine therapy decision making. It was found that BCI impacted the treatment recommendations for 42 out of a potential 141 patients and decreased patient decision conflict. Using a fact-based economic model, the researchers were also able to project an overall net saving of approximately $5190 per patient with BCI implementation.
The most read article from Lung Cancer Management this year was a research article exploring the clinical benefits of treating non-small cell lung cancer (NSCLC) patients with metformin in conjunction with immune checkpoint inhibitors (ICIs). The researchers, led by Muhammad Z Afzal (One Medical Center, NH, USA), determined the overall response rate and disease control rate in 50 NSCLC patients receiving ICIs, either with or without metformin. Although further prospective studies are needed to verify the long-term benefits of treating NSCLC with metformin in conjunction with ICIs, the study demonstrated that this treatment improves clinical outcomes for NSCLC patients.
Sticking with the theme of ICIs, the best performing article from Melanoma Management was also a research article, examining the immune-mediated adverse events in patients with metastatic melanoma receiving ICIs. Khor Zhong Wei (Ninewells Hospital, Dundee, UK) and colleagues discovered that 11.7% of the patients observed hypophysitis and 29.4% developed another form of immune-mediate adverse event. This study highlighted the high rate of hypophystisis in melanoma patients treated with ICIs and demonstrated the need for careful monitoring of symptoms.
Moving over to the International Journal of Hematologic Oncology, an article of particular interest is a case report, discussing a case of checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. The authors, led by Larisa Broglie (Medical College of Wisconsin, WI, USA) report on the case of a 4-year-old patient who received combined therapy with 5-azacitidine, nivolumab and ipilimumab and experienced no adverse effects over the 6 weeks of treatment. The treatment allowed for improved symptom control and gave the patient a better quality of life. Unfortunately, the patient passed away; however, this case highlights the feasibility of such a combination treatment and the authors recommend further research into the potential of this treatment strategy.
Finally, we have an Editorial article from the International Journal of Endocrine Oncology, written by Dan Granberg (Uppsala University, Sweden). Looking at bronchial carcinoids, the article provides an overview of the pathology, clinical symptoms, diagnosis and treatment of this neuroendocrine tumor type. The majority of patients with bronchial carcinoids can be cured by surgery, though the treatment of patients with metastatic disease remains a challenge. This article provides some potential alternative options for treatment, though still highlights the need for further studies to evaluate novel drugs.
That is it for our highlights of the year, though choosing only six articles was a challenge. All articles published in the oncology management journals are available to view open access now, so please visit the Future Medicine website to view each of the articles mentioned, as well as all past content to see if there is anything that we missed.
Compromising of CNS Oncology, Melanoma Management, Lung Cancer Management, Breast Cancer Management, International Journal of Hematologic Oncology, International Journal of Endocrine Oncology, Hepatic Oncology and Colorectal Cancer, the journals of our oncology management series present the latest advances and developments in the diagnosis and treatment of their respective cancer types.
The journals publish a wide range of article types, including from original research and reviews to editorials and commentaries. If you are interested in submitting to one of the journals and wish for more information, please contact the Editor.
To find out more journal highlights, make sure to check out journal highlights from Future Oncology
It's completely freeRegister